Research ArticleCancer

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma

See allHide authors and affiliations

Science Translational Medicine  10 May 2017:
Vol. 9, Issue 389, eaal2668
DOI: 10.1126/scitranslmed.aal2668

Rocaglates rocking multiple myeloma

Multiple myeloma is a difficult-to-treat hematologic malignancy, where the MYC oncoprotein often plays a key role by stimulating ribosome production and up-regulating protein translation to satisfy the needs of rapidly proliferating cancer cells. By performing a high-throughput screen, Manier et al. determined that small-molecule rocaglate derivatives are active in multiple myeloma. The authors focused on one lead rocaglate derivative and showed that it reversed the effects of MYC, blocked excessive translation, induced tumor cell apoptosis, and decreased tumor cell proliferation. The treatment was safe and effective in multiple mouse models, suggesting rocaglates as potential therapeutic candidates for multiple myeloma.